You are viewing an expired study

Pittsburgh, Pennsylvania 15213

  • Von Willebrand Disease


This study is testing the use of rhIL-11 (recombinant interleukin 11, Neumega) in individuals with Von Willebrand disease. The purpose is to evaluate: 1. if rhIL-11 corrects VWF (Von Willebrand Factor) levels to normal 2. if rhIL-11 and DDAVP together will boost VWF levels even higher 3. the onset, peak, and duration of rhIL-11 effect 4. if rhIL-11 is safe in individuals with Von Willebrand Disease

Study summary:

This is a prospective, single center, open-label, escalating dose Phase II comparison study of interleukin-11 (rhIL-11, Neumega) in subjects with type 1 Von Willebrand Disease (VWD). The purpose is to establish the clinical safety and hemostatic efficacy of rhIL-11 in individuals with type 1 Von Willebrand disease. Study subjects will include the following subjects: 1. age >= 18 years of age 2. diagnosis of VWD confirmed by: 2a) at least 2 of 4 abnormal vWD-related coagulation tests; 2b) a past bleeding history A total of 10-16 subjects are anticipated to be enrolled and complete the study. The specific aims of the study are: 1. to compare the hemostatic efficacy of three escalating doses of rhIL-11 2. to determine the biologic effects of rhIL-11 3. to determine whether DDAVP, when given after the seventh daily dose of rhIL-11, enhances hemostatic efficacy or rhIL-11 4. to compare the safety of three escalating doses of rhIL-11 Efficacy will be based on the number and percent increase of VWD-related coagulation tests into the normal range, or at least to 2-3 times baseline. Safety will be based on the number and frequency of adverse reactions, including fever, headache, fatigue, arthralgias, myalgias, fluid retention, and edema. The study will last up to 4 weeks per subject, and for 24 months for the entire study.


Inclusion Criteria: - Males and females 18 years of age or older - Confirmed VWD by 2 of 4 VWD coagulation tests abnormal - A past bleeding history - No hormone, oral contraceptive, estrogen use in past 8 weeks - Willingness to have blood drawn - Willingness to sign informed consent Exclusion Criteria: - Presence of other bleeding disorder, e.g. acquired VWD, thrombocytopenia - Use of estrogens, hormones, oral contraceptives in past 8 weeks - Use of immunomodulatory or experimental drugs or diuretics - Pregnant or lactating women - Past cardiac disease, congestive failure, arrhythmia (e.g. atrial fibrillation, atrial flutter), hypertension, MI, stroke, or thrombosis - Past allergic reaction to Neumega or DDAVP - Surgery within the past 8 weeks - Inability to comply with study protocol requirements - Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin, or NSAIDs - Treatment with DDAVP, cryoprecipitate, whole blood, plasma, and plasma derivatives containing FVIII, VWF within 5 days of study



Primary Contact:

Principal Investigator
Margaret V. Ragni, MD, MPH
University of Pittsburgh

Backup Contact:


Location Contact:

Pittsburgh, Pennsylvania 15213
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.